Inactive Instrument

News TapImmune Inc. Other OTC

Equities

US8760333091

End-of-day quote Other OTC Other stock markets
- ^USD	-

Mar. 27	North American Morning Briefing : Stocks Edge -2-	DJ
Mar. 25	Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies	Apr. 08	AQ
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results	Mar. 25	AQ
Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference	Mar. 22	AQ
North American Morning Briefing : Markets on Hold -2-	Mar. 20	DJ
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors	Mar. 13	AQ
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601	Jan. 22	AQ
Marker Therapeutics, Inc. Receives Approval from United States Adopted Name, Council and International Nonproprietary Names Expert Committee for ?Neldaleucel? as Nonproprietary Name for MT-601	Jan. 22	CI
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	Jan. 08	AQ
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization	Jan. 08	CI
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”	Dec. 21	AQ
Top Midday Gainers	Dec. 11	MT
Marker Therapeutics, Inc. Reports Clinical Update on the Apollo Study	Dec. 11	CI
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse	Dec. 11	AQ
Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q3 Revenue $257.6M	Nov. 09	MT
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates	Nov. 09	AQ
Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Marker Therapeutics, Inc. Announces Complete Response in First Lymphoma Patient Treated with MT-601 After Car T Relapse	23-09-11	CI
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse	23-09-11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News TapImmune Inc. Other OTC

Equities

US8760333091

Summary

Filters